R1 starts up with $78M, aiming for a better kidney drug [Yahoo! Finance]
Mineralys Therapeutics, Inc. (MLYS)
Company Research
Source: Yahoo! Finance
People with failing kidneys deal with a host of health issues, among them a complication that drives up phosphorus levels so high it can weaken bones and damage the heart. This hyperphosphatemia is common among those whose chronic kidney disease has progressed to the point of needing dialysis. But their treatment options can be tough to tolerate and involve taking multiple pills with each meal. R1 Therapeutics, a new biotechnology startup based in Redwood City, California, wants to change that. Armed with $77.5 million in Series A funding, the company has signed a deal with a Chinese pharmaceutical firm to bring into further clinical testing a drug it believes can advance upon available therapies for the condition. Typical treatments for hyperphosphatemia bind to the mineral in the gut. One, sold as Renvela , attaches to phosphate and keeps it from being absorbed in the bloodstream. Another, Xphozah prevents phosphate buildup by targeting a protein in the gastrointestinal tract
Show less
Read more
Impact Snapshot
Event Time:
MLYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MLYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MLYS alerts
High impacting Mineralys Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MLYS
News
- Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Mineralys Therapeutics (MLYS) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MLYS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sMarketBeat
- Mineralys Therapeutics (MLYS) had its "hold" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
- Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension [Yahoo! Finance]Yahoo! Finance
- Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval [Seeking Alpha]Seeking Alpha
MLYS
Earnings
- 3/12/26 - Beat
MLYS
Sec Filings
- 3/17/26 - Form 144
- 3/17/26 - Form 4
- 3/16/26 - Form 4
- MLYS's page on the SEC website